Evusheld Appears Less Effective Against Omicron for Patients With Blood Cancer
A single 150 mg dose of Evusheld demonstrated neutralizing activity against wild-type SARS-CoV-2 but not the omicron variant.
A single 150 mg dose of Evusheld demonstrated neutralizing activity against wild-type SARS-CoV-2 but not the omicron variant.
No specific causes of symptoms of postacute sequelae of SARS-CoV-2 infection identified.
Individuals with breakthrough infection have increased risk for death, postacute sequelae compared with contemporary controls.
Researchers sought to determine the role of LL-37 in patients with SARS-CoV-2 infection and whether it contributes to hypercoagulation.
Researchers sought to determine the case fatality rate in patients with CLL who were infected with SARS-CoV-2.
Receiving hormone replacement therapy within six months of recorded COVID-19 diagnosis linked to reduction in mortality.
The trial included 1678 children who received a third dose of the 3µg formulation at least 2 months after the second dose of a 2-dose series at a time when Omicron was the predominant variant.
Lower risk for developing chemosensory loss observed with alpha, delta, and omicron variants.
Inverse correlation sustained for up to six months following two doses of BNT162b2 in small cohort of healthy young and middle-aged adults.
More than twofold risk of acute pulmonary embolism and respiratory signs and symptoms among survivors aged 18 to 64, ≥65 years.